Literature DB >> 29328660

X-ray Structures of Target-Ligand Complexes Containing Compounds with Assay Interference Potential.

Erik Gilberg1,2, Michael Gütschow2, Jürgen Bajorath1.   

Abstract

Pan assay interference compounds (PAINS) have become a paradigm for compound classes that might cause artifacts in biological assays. PAINS-defining substructures are typically contained in larger compounds. We have systematically examined X-ray structures of protein-ligand complexes for compounds containing PAINS motifs. In 2874 X-ray structures, 1107 unique ligands with PAINS substructures belonging to 70 different classes were identified. PAINS most frequently detected in crystallographic ligands included a number of prominent candidates such as quinones, catechols, or Mannich bases. However, on the basis of X-ray data, the presence of specific ligand-target interactions and reactivity under assay conditions were not mutually exclusive. In some instances, reactivity of ligands was likely responsible for complex formation. Different categories of PAINS-containing ligands were distinguished, which aided in the interpretation of specific interactions versus potential assay artifacts. Careful consideration of structural data adds another dimension to the analysis of interference compounds.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29328660     DOI: 10.1021/acs.jmedchem.7b01780

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  4 in total

1.  A new ChEMBL dataset for the similarity-based target fishing engine FastTargetPred: Annotation of an exhaustive list of linear tetrapeptides.

Authors:  Shivalika Tanwar; Patrick Auberger; Germain Gillet; Mario DiPaola; Katya Tsaioun; Bruno O Villoutreix
Journal:  Data Brief       Date:  2022-04-11

Review 2.  Targeting the Small GTPase Superfamily through Their Regulatory Proteins.

Authors:  Janine L Gray; Frank von Delft; Paul E Brennan
Journal:  Angew Chem Int Ed Engl       Date:  2020-01-30       Impact factor: 16.823

Review 3.  Gains from no real PAINS: Where 'Fair Trial Strategy' stands in the development of multi-target ligands.

Authors:  Jianbo Sun; Hui Zhong; Kun Wang; Na Li; Li Chen
Journal:  Acta Pharm Sin B       Date:  2021-03-04       Impact factor: 11.413

4.  An Indole-Chalcone Inhibits Multidrug-Resistant Cancer Cell Growth by Targeting Microtubules.

Authors:  Hui Cong; Xinghua Zhao; Brian T Castle; Emily J Pomeroy; Bo Zhou; John Lee; Yi Wang; Tengfei Bian; Zhenyuan Miao; Wannian Zhang; Yuk Yin Sham; David J Odde; Craig E Eckfeldt; Chengguo Xing; Chunlin Zhuang
Journal:  Mol Pharm       Date:  2018-08-09       Impact factor: 5.364

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.